Effect of Lipo-PGE 1 on Health-related Quality of Life in Patients with Systemic Sclerosis and Systemic Lupus Erythematosus in Japan

Abstract

We investigated the effect of Lipo-PGE₁, a prostaglandin (PG) E₁ preparation used to treat cutaneous ulcers associated with systemic sclerosis (SS) and systemic lupus erythematosus (SLE), on health-related quality of life (HR-QOL) using the Medical Outcome Study 36-item Short-Form Health Survey (SF-36) questionnaire. A total of 192 SS and SLE patients were treated for 3 months. At baseline the scores for each of the five SF-36 subscales were significantly lower than the age- and sex-adjusted standard values for the Japanese general population. After treatment, mean (± SD) SF-36 scores for body pain and general health perception significantly increased from 48.6 ± 24.1 to 55.3 ± 26.1 and from 36.8 ± 16.7 to 40.2 ± 17, respectively. Emotional QOL parameters including vitality and mental health, however, showed no improvement. Physician-rated symptom scores significantly improved after administration of Lipo-PGE₁. In conclusion, Lipo-PGE₁ improved both cutaneous ulcers and HR-QOL, especially physical QOL.

Keywords

Prostaglandin Systemic sclerosis Systemic lupus erythematosus Health-related quality of life Clinical symptoms Cutaneous ulcers

References

Mizushima

Yanagawa

Hoshi

: Prostaglandin E1 is more effective, when incorporated in lipid micro spheres, for treatment of peripheral vascular disease in man. J Pharm Pharmacol 1983; 35: 666–667.

Mizushima

: Lipid micro spheres as novel drug carriers. Drugs Exp Clin Res 1985; 11: 595–600.

Hoshi

: Approved indications of lipo-PGE1 in Japan. Adv Drug Deliv Rev 1996; 20: 171–176.

Ware

Sherboune

: The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–489.

Stewart

Ware

: Measuring Functioning and Well-being. The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.

McHorney

Ware

Raczek

: The MOS 36-item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–263.

McHorney

Ware

JF Rachel

: The MOS 36-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40–66.

Fukuhara

Bito

Green

: Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 1037–1044.

Fukuhara

Suzukamo

: Manual of SF-36 V2 Japanese Version. Kyoto: Institute for Health Outcomes & Process Evaluation Research, 2004.

10.

Bito

Fukuhara

Green

: Comorbidity and health-related quality of life (abstract). Qual Life Res 1997; 6: 43.

11.

Fukuhara

Ware

Kosinski

: Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045–1053.

12.

Nakamura

Sakata

Fujita

: Epidemiological features of medicare recipients under the program to subsidize medical cost for intractable diseases. Jpn J Public Health 1991; 38: 525–533 [in Japanese].

13.

Shiokawa

Hashimoto

Honma

: Clinical evaluation of Lipo PGE1 in the treatment of peripheral circulatory involvement associated with collagen diseases. Jpn J Inflamm 1986; 6: 83–93.

14.

Esato

Fukuhara

: Pharmacoepidemiological study of Lipo-PGE1 on chronic arterial occlusive disease—essentially health-related QOL (SF-36). Jpn J Vasc Surg 2003; 12: 571–580.

15.

Fukuhara

Esato

: The effect of Liple® on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. Int Angiol 2004; 23: 238–245.